close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc
Search

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

38.33 3.9

Tugev "osta" hinnang

Hinna uuendus 4. dets 2025, 20:47 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.7

Max

38.38

Põhinäitajad

By Trading Economics

Sissetulek

11M

51M

Müük

39M

239M

P/E

Sektori keskmine

11.202

80.03

Aktsiakasum

1.08

Kasumimarginaal

21.242

Töötajad

268

EBITDA

14M

73M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+27.74% upside

Turustatistika

By TradingEconomics

Turukapital

358M

2B

Eelmine avamishind

34.43

Eelmine sulgemishind

38.33

Uudiste sentiment

By Acuity

44%

56%

144 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

DJ

Loe

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

DJ

Loe

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

DJ

Loe

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

DJ

Loe

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

DJ

Loe

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

DJ

Loe

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

DJ

Loe

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

DJ

Loe

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

DJ

Loe

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

DJ

Loe

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

DJ

Loe

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

DJ

Loe

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

DJ

Loe

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

DJ

Loe

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

DJ

Loe

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

DJ

Loe

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

DJ

Loe

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

DJ

Loe

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

DJ

Loe

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

DJ

Loe

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Loe

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

DJ

Loe

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

DJ

Loe

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

DJ

Loe

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

DJ

Loe

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

DJ

Loe

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

27.74% tõus

12 kuu keskmine prognoos

Keskmine 46 USD  27.74%

Kõrge 62 USD

Madal 32 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

9

Osta

0

Hoia

1

Müü

Põhineb 10 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Very Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

144 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,014.52

↓-1.97%

JNJ

Johnson and Johnson

202.07

↓-1.79%

ABBV

AbbVie Inc

228.32

↓-0.87%

UNH

UnitedHealth Group Inc

331.69

↓-2.2%

AZN

AstraZeneca PLC ADR

90.21

↓-0.75%
help-icon Live chat